Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...

IGM still has an immunology research partnership with biotech giant Sanofi, but the cuts to imvotamab and the other antibody leave the firm without any other projects in its listed pipeline.

May 8 - IGM Biosciences: Sanofi's termination of its 2022 collab with IGM Biosciences was the final nail in the coffin for the biotech’s research, given that it represented the last program in ...

who estimates that IGM will likely run out of cash sometime in 2027, even with sharply reduced expenditures and assuming future milestone payments from its early-stage Sanofi (SNY) collaboration.

IGM Biosciences (NASDAQ ... efforts and despite milestone payments attributed to a collaboration with Sanofi (SNY). “With no clinical assets, no clarity on strategic alternatives, and continuing ...